Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 4 minute read Pharma Industry News Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025. bySoujanya RaviAugust 3, 2025